A repeat dose, 28-day safety and bioavailability study of aripiprazole transdermal patches in healthy male volunteers.

Trial Profile

A repeat dose, 28-day safety and bioavailability study of aripiprazole transdermal patches in healthy male volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Psychiatric disorders
  • Focus Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 01 May 2017 Status changed from active, no longer recruiting to completed, as reported in an Aequus Pharmaceuticals media release.
    • 03 Apr 2017 Results published in an Aequus Pharmaceuticals media release.
    • 03 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting, according to an Aequus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top